Why carry out this study?

Data on the comparative effectiveness of risankizumab and deucravacitinib, two therapies approved for the treatment of moderate to severe psoriasis, are lacking.

This analysis used matching-adjusted indirect comparison methodology to compare risankizumab and deucravacitinib to better understand the effectiveness of these two treatments in patients with moderate to severe psoriasis.

What was learned from the study?

Patients treated with risankizumab had significantly higher rates of skin clearance, as well as significantly improved patient reported quality of life, compared to those treated with deucravacitinib.

This analysis demonstrated that, compared with deucravacitinib, patients with moderate to severe psoriasis had significantly greater improvements with risankizumab. These data may help inform healthcare providers in their treatment and management strategy for psoriasis.